I.M. Sechenov First Moscow State Medical University (Sechenov University)

The single-institution uncontrolled open-label trial is to optimize the anticoagulant therapy in the out-patient practice.

The study embraces patients who are advised to take the anticoagulant therapy for some reasons. The study has two phases - a retrospective part and a concurrent part. At the first phase, researchers analyze the compliance with the anticoagulant therapy in the real clinical practice. At the concurrent phase, researchers conduct a single-institution uncontrolled open-label trial to evaluate the effectiveness, safety of the anticoagulant therapy and compliance with it at the antithrombotic therapy control ward, and estimate the glomerular filtration rate in patients taking the anticoagulant therapy.

Inclusion criteria

• the age above 18
• indications for the anticoagulant therapy
• informed consent for inclusion into trials

Exclusion criteria

• denial to proceed in the trial

Non-inclusion criteria:

pregnancy and lactation

• Intracerebral hemorrhage within three preceding months
• severe mental disorders* which could possibly affect the anticoagulant therapy dosage schedule
• anemia and a decrease in Hb by ˂100 GM/DL*
• active gastroduodenal ulcer
• active bleeding during the preceding month
• other intensive bleeding instances as per the TIMI Score within three weeks before the inclusion
• severe hepatic impairment for over 10 points under the Child-Pugh Score
• oncology disease with the life expectancy less than one year